Join our email list!

Get daily updates delivered to your inbox
Thank you for subscribing

Novartis’ Gilenya Improves Cognition, Reduces Relapses and MS Lesions, Phase 4 Trial Shows

Novartis’ Gilenya Improves Cognition, Reduces Relapses and MS Lesions, Phase 4 Trial Shows
0
(0)

Thirty patients discontinued the study. A lot more were in the interferon beta-1b group than in  the Gilenya  group — 41 percent versus 8 percent.

Both therapies improved patients’ cognition, the trial showed. But patients in the interferon beta-1b group had more relapses and brain lesions than the Gilenya-treated patients.

Overall, the results supported the notion that both therapies can improve MS patients’ cognition. But “despite a disadvantage in terms of baseline characteristics [severity of the disease] and drop-out patterns, fingolimod treatment demonstrated significantly better effects than interferon beta-1 on MRI parameters and relapse rate,” the team concluded.

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
×
Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
Latest Posts
  • CMSC webinar series
  • infection risk
  • oral DMTs and safety
  • genetic variant

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?